Accelerating Sample to Decision: Automated LC-MS Workflows for RNA Therapeutics and Vaccines
Unlock the Power of LC-MS for RNA Therapeutics
Are you working with RNA-based therapeutics or vaccines?
Join our exclusive webinar to explore how LC-MS workflows can transform your approach to RNA characterization and quality analysis.
Why attend?
- Discover innovative LC-MS tools and workflows for RNA sequence and modification analysis.
- Learn best practices for achieving high-coverage RNA maps and leveraging automated informatics for streamlined analysis.
- Understand how LC-MS complements traditional and NGS sequencing for critical quality attributes.
What you’ll gain:
- Insights from Waters specialists on overcoming challenges in RNA characterization, including sgRNA/CRISPR and mRNA.
- Real-world case studies from industry experts applying LC-MS workflows to complex RNA molecules.
- Live Q&A with presenters and an expert panel to address your toughest questions.
Presentations:
- Innovative Workflows and Tolls for RNA Characterization and Attribute Monitoring. (Matt Gorton, Waters Corporation)
- Using Streamlined Bioinformatic Tools for Oligonucleotide Characterization. (Dr. Michael Rühl, BioSpring GmbH)
Reserve your spot today and take the next step toward mastering RNA analysis with LC-MS!
Presenter: Matthew Gorton (Principal Product Manager, Waters Corporation)
Matt works at Waters Corporation as a Principal Product Manager for Biopharma software applications. His work has focused on creating purpose-built analysis solutions for large and complex biomolecules such as sgRNA, used for CRISPR analysis, and mRNA, used in emerging biotherapeutics and vaccines. In addition to oligonucleotide mapping and sequencing software products, he also manages waters_connect software solutions which assist discovery, characterization, QC and manufacturing of a range of biomolecules.
Matt studied Genetics at Manchester University and has worked on both the Human Genome Project (HGP) and Cancer Genome Project (CGP) as a post-graduate at the Wellcome Trust Sanger Institute in Cambridge.
Presenter: Dr. Michael Rühl (Lab Head, Quality Control, Biospring Gmbh)
Michael studied pharmaceutical sciences from 2010 to 2015 at University of Frankfurt. From 2015 to 2019, he worked in the Karas group on covalently binding enzyme inhibitors and protein and peptide MS.
After his Ph.D. in pharmaceutical chemistry, he started at BioSpring as a lab head for bioanalytics and is now Senior Quality Control Researcher.
